

NATIONAL BLOOD AUTHORITY

Entity Resources and Planned Performance

National Blood Authority

Health Portfolio Entity

NBA

Section 1: Entity Overview and Resources

1.1:	Strategic Direction Statement	356
1.2:	Entity Resource Statement	356
1.3:	Budget Measures	358

Section 2: Outcomes and Planned Performance

2.1:	Outcomes and Performance Information	359
------	--	-----

Section 3: Explanatory Tables and Budgeted Financial Statements

3.1:	Explanatory Tables.....	364
3.2:	Budgeted Financial Statements	365

Section 1: Entity Overview and Resources

1.1 Strategic Direction Statement

The Australian Government, through the National Blood Authority (NBA), aims to ensure that Australia's blood supply is secure and well managed. The NBA was established by the Australian Government and State and Territory Governments, to coordinate policy, governance, funding and management of the blood banking and plasma product sector in Australia.

The NBA manages national contracts to secure the supply of safe and affordable blood products in Australia in accordance with the National Blood Agreement.

In the 2014-15 Budget, the Government announced the merger of the NBA and the Australian Organ and Tissue Donation and Transplant Authority to create a new independent body by 1 July 2015. The creation of a single entity will reduce running costs as well as streamlining and consolidating service delivery.

Implementation is progressing in the context of a whole-of-Government approach with other entity mergers to ensure new arrangements are effectively implemented.

The role and functions of the NBA are set out in the *National Blood Authority Act 2003*. The NBA is a Non-corporate Commonwealth entity under the *Public Governance, Performance and Accountability Act 2013*.

1.2 Entity Resources

Table 1.1 shows the total resources from all sources. The table summarises how resources will be applied by outcome and by administered and departmental classifications.

Table 1.1: NBA Resource Statement – Budget Estimates for 2015-16 as at Budget May 2015

	Estimated available appropriation	Estimate of prior year amounts available in	Proposed at Budget	Total estimate
	2014-15 \$'000	2015-16 \$'000	2015-16 \$'000	2015-16 \$'000
Ordinary annual services¹				
Departmental appropriation				
Prior year departmental appropriation and opening reserves	-	-	-	-
Departmental appropriation ²	6,938	-	5,912	5,912
s74 retained revenue receipts ³	-	-	-	-
Total	6,938	-	5,912	5,912
Administered resources¹				
Outcome 1	7,178	-	7,070	7,070
Total	7,178	-	7,070	7,070
Total ordinary annual services	14,116	-	12,982	12,982
Other services - Bill 2⁴				
Departmental non-operating				
Equity injections	-	-	-	-
Previous years' programmes	-	-	-	-
Total	-	-	-	-
Total other services	-	-	-	-
Total available annual appropriations	14,116	-	12,982	12,982
Total appropriations excluding Special Accounts	14,116	-	12,982	12,982
Special Accounts				
Opening balance ⁵	300,259	140,497	-	140,497
Appropriation receipts ⁶	14,116	-	12,982	12,982
Appropriation receipts - other agencies ⁷	535,345	-	721,297	721,297
Non-appropriation receipts to Special Accounts	440,502	-	498,349	498,349
Total Special Accounts	1,290,222	140,497	1,232,628	1,373,125
Total resourcing	1,304,338	140,497	1,245,610	1,386,107
Less appropriations drawn from annual or special appropriations above and credited to Special Accounts and/or payments to corporate entities through annual appropriations	(14,116)	-	(12,982)	(12,982)
Total net resourcing for NBA	1,290,222	140,497	1,232,628	1,373,125

All figures are GST exclusive.

1 Appropriation Bill (No. 1) 2015-16.

2 Includes an amount of \$0.063m in 2015-16 for the Departmental Capital Budget (refer to Table 3.2.5 for further details). For accounting purposes this amount has been designated as 'contributions by owners'.

3 Estimated retained revenue receipts under s74 of the *Public Governance, Performance and Accountability (PGPA) Act 2013*.

4 Appropriation Bill (No. 2) 2015-16.

5 Estimated opening balance for special accounts. For further information on special accounts see Table 3.1.1.

6 Appropriation receipts from NBA annual and special appropriations for 2015-16 included above.

7 Appropriation receipts from the Department of Health.

1.3 Budget Measures

Section 1.3 is not applicable to the NBA.

Section 2: Outcomes and Planned Performance

2.1 Outcomes and Performance Information

Access to a secure supply of safe and affordable blood products, including through national supply arrangements and coordination of best practice standards within agreed funding policies under the national blood arrangements

Outcome Strategy

The Australian Government aims to ensure that the public has timely access to safe blood and blood products. The NBA, on behalf of the Australian Government and State and Territory Governments, manages and coordinates national contracts to secure the supply of safe and affordable blood products in Australia in accordance with the National Blood Agreement. The NBA works with Governments and stakeholders to implement an efficient, demand-driven blood supply system that is highly responsive to clinical needs and based upon evidence and good clinical practice. The purchasing and supply arrangements for fresh, fractionated and recombinant products¹ will continue to be improved, including the further strengthening of risk mitigation arrangements.

Recognising the growing cost of blood products and the growing evidence of risk associated with unnecessary transfusions, the NBA will undertake a range of activities aimed at improving the clinical use of blood and blood products. Specifically, the NBA aims to improve the sustainability and performance of the sector through enhanced data capture and analysis. The NBA will also work to facilitate development and publication of evidence-based national clinical practice guidelines, informed by close engagement with clinicians.

¹ Fractionated products are those derived from human plasma whereas recombinant products are those manufactured through commercial scale expression of proteins from cell lines modified using recombinant gene technology.

NBA Budgeted Expenses and Resources

Table 2.1 provides an overview of the total expenses for NBA by programme.

Table 2.1: Budgeted Expenses for NBA

	2014-15 Estimated actual \$'000	2015-16 Budget \$'000	2016-17 Forward Year 1 \$'000	2017-18 Forward Year 2 \$'000	2018-19 Forward Year 3 \$'000
Programme 1.1: National blood agreement management					
Administered expenses					
Ordinary annual services					
(Appropriation Bill No. 1)	7,178	7,070	-	-	-
to the <i>National Blood Authority</i>					
Account	(7,178)	(7,070)	-	-	-
to the <i>National Managed Fund (Blood and Blood Products) Special Account</i>	-	-	-	-	-
Special accounts					
<i>National Blood Authority</i>					
Account	1,101,284	1,214,237	1,280,331	1,362,056	1,362,056
<i>National Managed Fund (Blood and Blood Products) Special Account</i>	-	-	-	-	-
Departmental expenses					
Departmental appropriation ¹	6,266	5,849	5,768	5,787	5,810
To <i>National Blood Authority</i>					
Account	(6,266)	(5,849)	(5,768)	(5,787)	(5,810)
Special Account					
<i>National Blood Authority</i>					
Account	10,160	9,269	9,468	9,501	9,593
Expenses not requiring appropriation in the budget year ²	483	483	483	483	483
Operating deficit (surplus)	(78)	(21)	(13)	(14)	(2)
Total for Programme 1.1	1,111,849	1,223,968	1,290,269	1,372,026	1,372,130
Total expenses for Outcome 1	1,111,849	1,223,968	1,290,269	1,372,026	1,372,130
	2014-15	2015-16			
Average staffing level (number)	53	53			

1 Departmental appropriation combines "Ordinary annual services (Appropriation Bill No. 1)" and "Revenue from independent sources (s74)".

2 Expenses not requiring appropriation in the Budget year is made up of depreciation expense, amortisation expense, makegood expense and audit fees.

Programme 1.1: National Blood Agreement Management

Programme Objectives

Secure the supply of blood and blood products

The NBA works with State and Territory Governments and suppliers so that requirements for day-to-day product supply and future demand are well managed. In 2015-16, the NBA will negotiate with the Australian Red Cross Blood Service (Blood Service) to finalise a new Deed of Agreement to provide fresh blood products for Australia. In addition, the NBA will implement the second phase of the national service requirements and standards project. The project will improve service arrangements between the Blood Service and health providers for the supply of blood products. The NBA will undertake new procurement actions for a range of imported plasma and recombinant products.²

Improve risk management and blood sector performance

In 2015-16, the NBA will undertake a number of initiatives to improve the efficiency and effectiveness of the blood supply network. A high priority will be the implementation of new arrangements for the clinical and administrative management of immunoglobulin (Ig) and an associated supporting national information and communication technology (ICT) system. These arrangements will seek to ensure the demand for Ig reflects appropriate clinical practice. The NBA will continue the implementation of the National Inventory Management Framework with health providers to ensure red blood cell stocks are managed in the most efficient manner, including the piloting of an additional platelet inventory management module. The NBA will further consolidate savings from the second year of implementing the national wastage reduction strategy, approved by Governments in 2013.

The NBA will work with States and Territories and all suppliers to complete the nationwide implementation of BloodNet, which allows real time inventory and wastage monitoring, and will extend the use of this system to allow for ordering of products from other contracted suppliers in addition to the Blood Service. The NBA will complete the development of a new ICT system to support the improved governance and management of intravenous Ig.

Promote the safe and efficient use of blood and blood products

In 2015-16, the NBA will finalise the sixth module of the Patient Blood Management Guidelines, initiate the revision of Module 1³ including piloting a revised guideline development process, and publishing guidelines for the comprehensive management of haemophilia. The revision of Module 1 is required to ensure the currency of the guidelines. The NBA will work collaboratively with

² Recombinant products are those manufactured through commercial scale expression of proteins from cell lines modified using recombinant gene technology.

³ Module 1: Critical Bleeding/Massive Transfusion, is intended to assist and guide health care professionals in making clinical decisions when managing patients with critical bleeding who require or are likely to require massive transfusion.

stakeholders in the sector to continue the implementation of the Patient Blood Management Guidelines Implementation Strategy.

Programme 1.1: Deliverables

Qualitative Deliverables for Programme 1.1

Secure the supply of blood and blood products

Qualitative Deliverable	2015-16 Reference Point or Target
New Australian Red Cross Blood Service contract arrangements are progressed.	Finalise a new Deed of Agreement with the Australian Red Cross.

Improve risk management and blood sector performance

Qualitative Deliverable	2015-16 Reference Point or Target
New immunoglobulin (Ig) governance arrangements are implemented.	The Ig Governance ICT system is implemented and supports all supply authorisation for Ig.

Promote the safe and efficient use of blood and blood products

Qualitative Deliverable	2015-16 Reference Point or Target
National data strategy and National Patient Blood Management (PBM) Guidelines Implementation Strategy are progressed.	Performance scorecard and comparator benchmark data is published. The standards and minimum data sets for blood sector data are implemented. The National Reference Set of PBM implementation tools is published.

Quantitative Deliverables for Programme 1.1

Promote the safe and efficient use of blood and blood products

Quantitative Deliverable	2014-15 Revised Budget	2015-16 Budget Target	2016-17 Forward Year 1	2017-18 Forward Year 2	2018-19 Forward Year 3
Number of clinical practice guidelines published.	1	2	1	2	2

Programme 1.1: Key Performance Indicators

Qualitative Key Performance Indicators for Programme 1.1

Secure the supply of blood and blood products

Qualitative Indicator	2015-16 Reference Point or Target
Provision of an adequate, affordable and secure supply of blood and blood products.	Blood products are available to meet clinical need.

Promote the safe and efficient use of blood and blood products

Qualitative Indicator	2015-16 Reference Point or Target
There is a robust framework supporting best practice management and use of blood and blood products.	A sustained improvement in the management and use of blood products.

Quantitative Key Performance Indicators for Programme 1.1

Secure the supply of blood and blood products

Quantitative Indicator	2014-15 Revised Budget	2015-16 Budget Target	2016-17 Forward Year 1	2017-18 Forward Year 2	2018-19 Forward Year 3
Variance between actual and NBA estimated demand for supply of products.	<5%	<5%	<5%	<5%	<5%

Improve risk management and blood sector performance

Quantitative Indicator	2014-15 Revised Budget	2015-16 Budget Target	2016-17 Forward Year 1	2017-18 Forward Year 2	2018-19 Forward Year 3
Percentage of national blood supply processed by laboratories interfaced to BloodNet.	20%	30%	40%	50%	60%

Section 3: Explanatory Tables and Budgeted Financial Statements

Section 3 presents explanatory tables and budgeted financial statements which provide a comprehensive snapshot of entity finances for the 2015-16 Budget year. It explains how budget plans are incorporated into the financial statements and provides further details of the reconciliation between appropriations and programme expenses, movements in administered funds, special accounts and Australian Government Indigenous expenditure.

3.1 Explanatory Tables

3.1.1 Movement of Administered Funds Between Years

Section 3.1.1 is not applicable to the NBA.

3.1.2 Special Accounts

Special accounts provide a means to set aside and record amounts used for specified purposes. Special accounts can be created by a Finance Minister’s determination under section 78 of the PGPA Act or under separate enabling legislation (section 80 of the PGPA Act refers). Table 3.1.2 shows the expected additions (receipts) and reductions (payments) for each account used by the NBA.

Table 3.1.1: Estimates of Special Account Flows and Balances

		Opening balance 2015-16 2014-15	Appropriation receipts 2015-16 2014-15	Other receipts 2015-16 2014-15	Payments 2015-16 2014-15	Closing balance 2015-16 2014-15
	Outcome	\$'000	\$'000	\$'000	\$'000	\$'000
National Blood Authority Account ¹ (A)	1	131,099 291,524	7,070 7,178	1,254,092 1,025,111	1,305,673 1,192,714	86,588 131,099
National Blood Authority Account ¹ (D)	1	9,067 8,404	5,912 6,938	3,673 4,147	9,588 10,422	9,064 9,067
National Managed Fund (Blood and Blood Products) Special Account ^{2, 3} (A)	1	331 331	- -	62,634 47,342	62,634 47,342	331 331
Total Special Accounts 2015-16 Estimate		140,497	12,982	1,320,399	1,377,895	95,983
<i>Total Special Accounts 2014-15 estimate actual</i>		<i>300,259</i>	<i>14,116</i>	<i>1,076,600</i>	<i>1,250,478</i>	<i>140,497</i>

Other Trust Money - s78 PGPA Act has been abolished.

D = Departmental; A = Administered

1 National Blood Authority Act 2003 - s80 PGPA Act

2 s78 PGPA Act

3 In 2010-11, the NBA was granted investment powers for the National Managed Fund Special Account. Payments represent the purchase of investments.

3.1.3 Australian Government Indigenous Expenditure (AGIE)

Section 3.1.3 is not applicable to the NBA.

3.2 Budgeted Financial Statements

3.2.1 Differences in Entity Resourcing and Financial Statements

Section 3.2.1 is not applicable to the NBA.

3.2.2 Analysis of Budgeted Financial Statements

An analysis of the NBA's budgeted financial statements for 2015-16 is provided below.

Departmental Resources

Comprehensive Income Statement

This statement provides a picture of the expected financial results for the National Blood Authority by identifying accrual expenses and revenues showing the net cost of services.

NBA operational costs are funded jointly by the Australian, State and Territory Governments on a 63:37 per cent basis through annual contributions. All NBA receipts and payments are accounted through special accounts.

The NBA is expecting a break even position for the budget year and all forward years.

The income statement deficit in the budget year and forward years is as a result of the Government's decision to no longer fund for depreciation via an operating appropriation.

Balance Sheet

Special account accumulated funds are held within the Official Public Account and included as Receivables in the Balance Sheet. The NBA always maintains sufficient accumulated funds to cover employee entitlements and other liabilities.

The value of intangible assets will fall over 2015-16 reflecting the use and amortisation of the integrated data management system before increasing again in the forward years due to replacement systems being developed. Other non-financial assets and liabilities will remain broadly stable over the period.

Administered Resources

Schedule of Budgeted Income and Expenses Administered on Behalf of Government

The NBA administered accounts include contributions from all states and territories and the Australian Government for the supply of blood and blood related products for 2015-16. Each year the COAG Health Council (formerly the Standing Council on Health) approves an Annual National Supply Plan and Budget which is formulated by the NBA from demand estimates provided by the States and Territories.

Schedule of Budgeted Assets and Liabilities Administered on Behalf of Government

The schedule of budgeted assets and liabilities administered on behalf of Government illustrates normal movements in non-financial assets and liabilities. The balance of Receivables represents GST payments made to suppliers which are recoverable from the Australian Taxation Office. Other non-financial assets represent a prepayment to the Australian Red Cross Blood Service under the Output Based Funding Model agreement.

During 2010-11, the NBA was granted investment powers for the National Managed Fund special account. The increase in Cash and Investments over the forward years represents annual contributions received as well as re-investment of interest income.

3.2.3 Budgeted Financial Statements Tables

Table 3.2.1: Comprehensive Income Statement (showing net cost of services) for the period ended 30 June

	Estimated actual 2014-15 \$'000	Budget estimate 2015-16 \$'000	Forward estimate 2016-17 \$'000	Forward estimate 2017-18 \$'000	Forward estimate 2018-19 \$'000
EXPENSES					
Employee benefits	6,288	6,405	6,598	6,747	6,901
Supplier expenses	3,881	2,930	2,944	2,827	2,777
Depreciation and amortisation	389	389	389	389	389
Finance costs	7	7	7	7	7
Total expenses	10,565	9,731	9,938	9,970	10,074
LESS:					
OWN-SOURCE INCOME					
Revenue					
Other revenue	3,894	3,420	3,700	3,714	3,783
Total revenue	3,894	3,420	3,700	3,714	3,783
Gains					
Other	94	94	94	94	94
Total gains	94	94	94	94	94
Total own-source income	3,988	3,514	3,794	3,808	3,877
Net cost of (contribution by) services	6,577	6,217	6,144	6,162	6,197
Revenue from Government	6,266	5,849	5,768	5,787	5,810
Surplus (Deficit)	(311)	(368)	(376)	(375)	(387)
Surplus (Deficit) attributable to the Australian Government	(311)	(368)	(376)	(375)	(387)
OTHER COMPREHENSIVE INCOME					
Changes in asset revaluation reserves	-	-	-	-	-
Total other comprehensive income	-	-	-	-	-
Total comprehensive income attributable to the Australian Government	(311)	(368)	(376)	(375)	(387)
Note: Reconciliation of comprehensive income attributable to the agency					
	2014-15 \$'000	2015-16 \$'000	2016-17 \$'000	2017-18 \$'000	2018-19 \$'000
Total comprehensive income (loss) attributable to the Australian Government	(311)	(368)	(376)	(375)	(387)
plus non-appropriated expenses depreciation and amortisation expenses	389	389	389	389	389
Total comprehensive income (loss) attributable to the agency	78	21	13	14	2

Table 3.2.2: Budgeted Departmental Balance Sheet (as at 30 June)

	Estimated actual 2014-15 \$'000	Budget estimate 2015-16 \$'000	Forward estimate 2016-17 \$'000	Forward estimate 2017-18 \$'000	Forward estimate 2018-19 \$'000
ASSETS					
Financial assets					
Cash and cash equivalents	29	29	29	29	29
Receivables	8,633	8,558	8,202	7,846	7,477
Total financial assets	8,662	8,587	8,231	7,875	7,506
Non-financial assets					
Land and buildings	1,060	936	1,062	1,138	1,114
Property, plant and equipment	826	804	943	1,138	1,419
Intangibles	583	440	787	1,132	1,495
Other	100	100	100	100	100
Total non-financial assets	2,569	2,280	2,892	3,508	4,128
Total assets	11,231	10,867	11,123	11,383	11,634
LIABILITIES					
Payables					
Suppliers	497	397	397	397	397
Other payables	564	564	564	564	564
Total payables	1,061	961	961	961	961
Provisions					
Employees	1,548	1,589	1,589	1,589	1,589
Other provisions	412	412	412	412	412
Total provisions	1,960	2,001	2,001	2,001	2,001
Total liabilities	3,021	2,962	2,962	2,962	2,962
Net Assets	8,210	7,905	8,161	8,421	8,672
EQUITY					
Contributed equity	3,250	3,313	3,945	4,580	5,218
Reserves	359	359	359	359	359
Retained surpluses or accumulated deficits	4,601	4,233	3,857	3,482	3,095
Total equity	8,210	7,905	8,161	8,421	8,672

Table 3.2.3: Departmental Statement of Changes in Equity — summary of movement (Budget year 2015-16)

	Retained earnings \$'000	Asset revaluation reserve \$'000	Contributed equity/ capital \$'000	Total equity \$'000
Opening balance as at 1 July 2015				
Balance carried forward from previous period	4,601	359	3,250	8,210
Surplus (deficit) for the period	(368)	-	-	(368)
Appropriation (equity injection)	-	-	-	-
Capital budget - Bill 1 (DCB)	-	-	63	63
Estimated closing balance as at 30 June 2016	4,233	359	3,313	7,905

DCB = Departmental Capital Budget.

**Table 3.2.4: Budgeted Departmental Statement of Cash Flows
(for the period ended 30 June)**

	Estimated actual 2014-15 \$'000	Budget estimate 2015-16 \$'000	Forward estimate 2016-17 \$'000	Forward estimate 2017-18 \$'000	Forward estimate 2018-19 \$'000
OPERATING ACTIVITIES					
Cash received					
Appropriations	6,266	5,849	5,768	5,787	5,810
Net GST received	253	253	253	253	253
Other cash received	3,894	3,420	3,700	3,714	3,783
Cash from the Official Public Account	132	-	227	225	239
Total cash received	10,545	9,522	9,948	9,979	10,085
Cash used					
Employees	6,329	6,405	6,598	6,747	6,901
Suppliers	3,788	2,937	2,951	2,834	2,784
Net GST paid	38	29	30	28	29
Cash to the Official Public Account	-	114	-	-	-
Total cash used	10,155	9,485	9,579	9,609	9,714
Net cash from (or used by) operating activities	390	37	369	370	371
INVESTING ACTIVITIES					
Cash used					
Purchase of property, plant and equipment	1,062	100	1,001	1,005	1,009
Total cash used	1,062	100	1,001	1,005	1,009
Net cash from (or used by) investing activities	(1,062)	(100)	(1,001)	(1,005)	(1,009)
FINANCING ACTIVITIES					
Cash received					
Capital budget - Bill 1 (DCB)	672	63	632	635	638
Total cash received	672	63	632	635	638
Net cash from (or used by) financing activities	672	63	632	635	638
Net increase (or decrease) in cash held	-	-	-	-	-
Cash and cash equivalents at the beginning of the reporting period	29	29	29	29	29
Cash and cash equivalents at the end of the reporting period	29	29	29	29	29

DCB = Departmental Capital Budget.

Table 3.2.5: Departmental Capital Budget Statement (for the period ended 30 June)

	Estimated actual 2014-15 \$'000	Budget estimate 2015-16 \$'000	Forward estimate 2016-17 \$'000	Forward estimate 2017-18 \$'000	Forward estimate 2018-19 \$'000
CAPITAL APPROPRIATIONS					
Capital budget - Bill 1 (DCB)	672	63	632	635	638
Total capital appropriations	672	63	632	635	638
Total new capital appropriations represented by:					
Purchase of non-financial assets	672	63	632	635	638
Total items	672	63	632	635	638
PURCHASE OF NON-FINANCIAL ASSETS					
Funded by capital appropriation - DCB ¹	672	63	632	635	638
Funded internally from departmental resources	390	37	369	370	371
Total acquisitions of non-financial assets	1,062	100	1,001	1,005	1,009
RECONCILIATION OF CASH USED TO ACQUIRE ASSETS TO ASSET MOVEMENT TABLE					
Total purchases	1,062	100	1,001	1,005	1,009
Total cash used to acquire assets	1,062	100	1,001	1,005	1,009

DCB = Departmental Capital Budget.

1 Does not include annual finance lease costs. Includes purchases from current and previous years' Departmental Capital Budgets.

Table 3.2.6: Statement of Asset Movements (Budget year 2015-16)

	Buildings	Other property, plant and equipment	Intangibles	Total
	\$'000	\$'000	\$'000	\$'000
As at 1 July 2015				
Gross book value	1,184	945	4,047	6,176
Accumulated depreciation/amortisation and impairment	(124)	(119)	(3,464)	(3,707)
Opening net book balance	1,060	826	583	2,469
CAPITAL ASSET ADDITIONS				
Estimated expenditure on new or replacement assets				
By purchase - appropriation equity	-	-	-	-
By purchase - appropriation ordinary annual services	-	61	2	63
By purchase - internal resources	-	36	1	37
Total additions	-	97	3	100
Other movements				
Depreciation/amortisation expense	(124)	(119)	(146)	(389)
Total other movements	(124)	(119)	(146)	(389)
as at 30 June 2016				
Gross book value	1,184	1,042	4,050	6,276
Accumulated depreciation/amortisation and impairment	(248)	(238)	(3,610)	(4,096)
Closing net book balance	936	804	440	2,180

Table 3.2.7: Schedule of Budgeted Income and Expenses Administered on Behalf of Government (for the period ended 30 June)

	Estimated actual 2014-15 \$'000	Budget estimate 2015-16 \$'000	Forward estimate 2016-17 \$'000	Forward estimate 2017-18 \$'000	Forward estimate 2018-19 \$'000
INCOME ADMINISTERED ON BEHALF OF GOVERNMENT					
Revenue					
Non-taxation					
Other sources of non-taxation revenues	930,597	1,159,164	1,255,317	1,338,312	1,428,241
Total non-taxation	930,597	1,159,164	1,255,317	1,338,312	1,428,241
Total revenues administered on behalf of Government	930,597	1,159,164	1,255,317	1,338,312	1,428,241
Total income administered on behalf of Government	930,597	1,159,164	1,255,317	1,338,312	1,428,241
EXPENSES ADMINISTERED ON BEHALF OF GOVERNMENT					
Employee benefits	247	57	-	-	-
Suppliers	1,091,967	1,205,116	1,280,331	1,362,056	1,362,056
Grants	8,577	8,577	-	-	-
Depreciation and amortisation	493	487	-	-	-
Total expenses administered on behalf of Government	1,101,284	1,214,237	1,280,331	1,362,056	1,362,056

Table 3.2.8: Schedule of Budgeted Assets and Liabilities Administered on Behalf of Government (as at 30 June)

	Estimated actual 2014-15 \$'000	Budget estimate 2015-16 \$'000	Forward estimate 2016-17 \$'000	Forward estimate 2017-18 \$'000	Forward estimate 2018-19 \$'000
ASSETS ADMINISTERED ON BEHALF OF GOVERNMENT					
Financial assets					
Cash and cash equivalent	349	363	377	377	377
Receivables	25,684	27,020	27,020	27,854	27,854
Investments	115,454	121,026	131,698	142,370	142,370
Total financial assets	141,487	148,409	159,095	170,601	170,601
Non-financial assets					
Property, plant and equipment	98	47	47	47	47
Intangibles	757	321	321	321	321
Inventories	87,059	87,559	88,381	88,381	88,381
Other	76,032	76,032	76,032	76,032	76,032
Total non-financial assets	163,946	163,959	164,781	164,781	164,781
Total assets administered on behalf of Government	305,433	312,368	323,876	335,382	335,382
LIABILITIES ADMINISTERED ON BEHALF OF GOVERNMENT					
Interest bearing liabilities					
Payables					
Suppliers	79,786	80,888	80,991	80,991	80,991
Total payables	79,786	80,888	80,991	80,991	80,991
Total liabilities administered on behalf of Government	79,786	80,888	80,991	80,991	80,991

Table 3.2.9: Schedule of Budgeted Administered Cash Flows (for the period ended 30 June)

	Estimated actual 2014-15 \$'000	Budget estimate 2015-16 \$'000	Forward estimate 2016-17 \$'000	Forward estimate 2017-18 \$'000	Forward estimate 2018-19 \$'000
OPERATING ACTIVITIES					
Cash received					
Commonwealth contributions	535,345	721,297	781,772	833,954	890,500
State and Territory contributions	389,266	432,295	467,973	498,786	532,169
Interest	5,336	5,072	5,572	5,572	5,572
Net GST received	100,500	100,500	100,500	100,500	100,500
Other	177,973	73,300	51,381	58,382	(19,807)
Total cash received	1,208,420	1,332,464	1,407,198	1,497,194	1,508,934
Cash used					
Employees	247	57	-	-	-
Suppliers	1,085,126	1,198,442	1,269,556	1,351,384	1,362,056
Grant payments	8,577	8,577	-	-	-
Net GST paid	109,370	120,702	126,956	135,138	136,206
Total cash used	1,203,320	1,327,778	1,396,512	1,486,522	1,498,262
Net cash from (or used by) operating activities	5,100	4,686	10,686	10,672	10,672
INVESTING ACTIVITIES					
Cash received					
Proceeds from sale of investments	41,356	57,062	-	-	-
Total cash received	41,356	57,062	-	-	-
Cash used					
Purchase of investments	46,442	61,734	10,672	10,672	10,672
Total cash used	46,442	61,734	10,672	10,672	10,672
Net cash from (or used by) investing activities	(5,086)	(4,672)	(10,672)	(10,672)	(10,672)
Net increase (or decrease) in cash held	14	14	14	-	-
Cash at beginning of reporting period	335	349	363	377	377
Cash from Official Public Account for:					
- special accounts	1,242,584	1,382,442	1,407,184	1,497,194	1,508,934
- appropriations	7,178	7,070	-	-	-
Cash to Official Public Account for:					
- special accounts	1,249,762	1,389,512	1,407,184	1,497,194	1,508,934
- appropriations	-	-	-	-	-
Cash at end of reporting period	349	363	377	377	377